General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KIWMM
ADC Name
CN116916962A-ADC-B19
Synonyms
ADC-B19
   Click to Show/Hide
Organization
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Drug Status
Investigative
Drug-to-Antibody Ratio
2
Structure
Antibody Name
hIgG1
 Antibody Info 
Antigen Name
Undisclosed
Payload Name
Compound I-5c
 Payload Info 
Linker Name
CN116916962A-C-39-linker
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
C-39
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
3.09
nM
CVCL_0006
Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 3.09 nM High hCCR2 expression (hCCR2+++)
Method Description
THP 1, 15,000cells/254uL per welld were plated at set in 384 well flat plate, in the appropriate growth media. The cell plates were dosed with 5uL of the hCCR2 targeting-ADC samples and then incubated at 37°C for 20 hours. At the end of the incubation 10uL/well of the QUANTJ-LucTM (InvivoGenftrep-qlc1) were added and luminescence was measured immediately using the LeadSeeker.

   Click to Show/Hide
In Vitro Model Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia THP1 cells CVCL_0006
References
Ref 1 Antibody-drug conjugates